Mabion S.A. (WAR:MAB) — Market Cap & Net Worth
Market Cap & Net Worth: Mabion S.A. (MAB)
Mabion S.A. (WAR:MAB) has a market capitalization of $33.89 Million (zł123.16 Million) as of June 17, 2026. Listed on the WAR stock exchange, this Poland-based company holds position #23403 globally and #221 in its home market, demonstrating a 4.53% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Mabion S.A.'s stock price zł7.62 by its total outstanding shares 16162326 (16.16 Million). Review Mabion S.A. (MAB) financial obligations to assess the company's total debt and financial obligations.
Mabion S.A. Market Cap History: 2015 to 2026
Mabion S.A.'s market capitalization history from 2015 to 2026. Data shows change from $208.88 Million to $33.89 Million (-15.98% CAGR).
Mabion S.A. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Mabion S.A.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.97x
Mabion S.A.'s market cap is 1.97 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $92.30 Million | $1.59 Million | -$57.19 Million | 58.05x | N/A |
| 2021 | $271.78 Million | $56.87 Million | $1.90 Million | 4.78x | 142.82x |
| 2022 | $93.41 Million | $163.98 Million | $23.19 Million | 0.57x | 4.03x |
| 2023 | $80.73 Million | $151.68 Million | $41.27 Million | 0.53x | 1.96x |
| 2024 | $39.59 Million | $69.02 Million | -$6.33 Million | 0.57x | N/A |
| 2025 | $31.05 Million | $15.76 Million | -$62.61 Million | 1.97x | N/A |
Competitor Companies of MAB by Market Capitalization
Companies near Mabion S.A. in the global market cap rankings as of June 17, 2026.
Key companies related to Mabion S.A. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
Mabion S.A. Historical Marketcap From 2015 to 2026
Between 2015 and today, Mabion S.A.'s market cap moved from $208.88 Million to $ 33.89 Million, with a yearly change of -15.98%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | zł33.89 Million | +9.17% |
| 2025 | zł31.05 Million | -21.57% |
| 2024 | zł39.59 Million | -50.96% |
| 2023 | zł80.73 Million | -13.57% |
| 2022 | zł93.41 Million | -65.63% |
| 2021 | zł271.78 Million | +194.46% |
| 2020 | zł92.30 Million | -73.05% |
| 2019 | zł342.50 Million | -11.09% |
| 2018 | zł385.21 Million | -23.23% |
| 2017 | zł501.75 Million | +51.96% |
| 2016 | zł330.18 Million | +58.07% |
| 2015 | zł208.88 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Mabion S.A. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $33.89 Million USD |
| MoneyControl | $33.89 Million USD |
| MarketWatch | $33.89 Million USD |
| marketcap.company | $33.89 Million USD |
| Reuters | $33.89 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Mabion S.A.
Mabion S.A., a biopharmaceutical company, provides services as a contract development and manufacturing organization in the process development, analytics, and manufacturing of biologic medicines in Poland. It offers drug substance manufacturing, fill and finish, gene to vial end-to-end development, process development, analytics, and banking services. In addition, it offers cell line development… Read more